Former member of the National Advisory Council on Drug Abuse (NACDA) and National Institute on Drug Abuse (NIDA) Joins Ehave,...
July 06 2021 - 8:30AM
Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of
digital therapeutics for the psychedelic and mental health sectors,
announced today Dr. Bankole A. Johnson has agreed to join the
Company's Medical Advisory Board. As a member of Ehave’s Medical
Advisory Board, Dr. Johnson’s primary responsibilities will be to
assist and advise the Company on human trials for its cognitive and
psychedelic opportunities, as well as assist and advise the Company
on mental health analytical platforms.
Bankole A. Johnson, DSc, MD, MPhil, FRCPsych is
a licensed physician and board-certified psychiatrist throughout
Europe and the United States who served as Alumni Professor and
Chairman of the Department of Psychiatry and Neurobehavioral
Sciences at the University of Virginia. Dr. Johnson's primary area
of research expertise is the psychopharmacology of medications for
treating addictions, and he is well known in the field for his
discovery that topiramate, a gamma-aminobutyric acid (GABA)
facilitator and glutamate antagonist, an effective treatment for
alcoholism. Professor Johnson also received national media
attention for his appearance in the Home Box Office (HBO) original
documentary feature, "Addiction", which won the prestigious
Governors Award, a special Emmy Award, from the Academy of
Television Arts and Sciences. Professor Johnson recently accepted
an appointment to join the University of Maryland as the Chairman
of Psychiatry and to lead a Brain Science Research Consortium in
the neurosciences.
Dr. Johnson is currently a member of the
Extramural Advisory Board for NIH/NIAAA, an NIH Roadmap Consultant,
a Fellow in the Royal College of Psychiatrists, a Distinguished
Fellow of the American Psychiatric Association, and a Fellow in the
American College of Neuropsychopharmacology. In 2019, Dr. Johnson
received the R. Brinkley Smithers award from the American
Association of Addiction Medicine. He was also listed in "Best
Doctors in America" in 2007, 2009, and 2010. In 2004 Dr. Johnson
was inducted into the Texas Hall of Fame for Science, Mathematics
and Technology. He served on the National Advisory Council for
NIH/NIDA from 2004 – 2007 and was a member of the Medications
Development Subcommittee of NIDA's Advisory Council on Drug Abuse
during the same period. Dr. Johnson has also been presented with
the prestigious Jack Mendelson Award from the NIAAA and the Solomon
Carter Fuller Award by the American Psychiatric Association.
Dr. Bankole Johnson was also the founder of
NASDAQ listed Adial Pharmaceuticals (NASDAQ: ADIL) and currently
serves as its Chief Medical Officer. Dr. Johnson was recently
featured as a guest on The Black News Channel offering insights
into the long-term effects of the COVID-19 pandemic on mental
health and addiction. A replay of the interview is available on the
media section of the Company’s website at:
https://www.adialpharma.com/newsroom/media/.
Dr. Bankole Johnson was featured in a March 5th
2021 Forbes article, “Dr. Bankole Johnson Believes Beauty Begins In
The Brain.”
https://www.forbes.com/sites/rebeccasuhrawardi/2021/03/05/dr-bankole-johnson-believes-beauty-begins-in-the-brain/?sh=74b75f986c3f
Bankole A. Johnson, DSc, MD, MPhil, FRCPsych
said, "I am pleased to join the Ehave Medical Advisory Board and
look forward to working towards bringing psychedelic-assisted
therapies to patients experiencing substance use issues. The
opportunity exists to meld our evolving understanding of the
biological mechanisms underlying addiction with the personalized
psycho-spiritual approach being realized by psychedelic medicine."
"Ehave is passionate about creating a singular and integrated
experience for people in their healthcare journeys. I welcome the
opportunity to join them in their efforts.”
Ben Kaplan, CEO of Ehave, Inc. said, “We are
very fortunate to include such an esteemed medical professional as
Dr. Johnson as a member of our Medical Advisory Board. His work
integrates the neuroscience and behavioral aspects of addiction
medicine with the goal of formulating a more thorough understanding
of the basis of drug-seeking behavior and developing effective
treatments. We look forward to Dr. Johnson's expertise as we expand
our mental health analytical platform and enter clinical
trials."
About Ehave, Inc.
Ehave, Inc. is a provider of digital
therapeutics delivering evidence-based therapeutic interventions to
patients. Our primary focus is on improving the standard care in
therapeutics to prevent or treat brain disorders or diseases
through the use of digital therapeutics, psychedelics,
independently or together, with medications, devices, and other
therapies to optimize patient care and health outcomes meeting
privacy and HIPAA & GDPR Compliant. Our main product is the
Ehave Dashboard which is a mental health informatics platform that
allows clinicians to make objective and intelligent decisions
through data insight using Blockchain technology. The Ehave
dashboard offers Offline Encrypted Digital Records Empowering
Healthcare providers and patients and it's a powerful machine
learning and artificial intelligence platform using artificial
intelligence to extract deep insights from audio, video and text to
improve research with a growing set of advanced tools and
applications developed by Ehave and its leading partners. This
empowers patients, healthcare providers, and payers to address a
wide range of conditions through high quality, safe, and effective
data-driven involvement with intelligent and accessible tools.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words. Forward-looking statements are based
on certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company's
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements: (i) the initiation,
timing, progress and results of the Company’s research,
manufacturing and other development efforts; (ii) the Company’s
ability to advance its products to successfully complete
development and commercialization; (iii) the manufacturing,
development, commercialization, and market acceptance of the
Company’s products; (iv) the lack of sufficient funding to finance
the product development and business operations; (v) competitive
companies and technologies within the Company’s industry and
introduction of competing products; (vi) the Company’s ability to
establish and maintain corporate collaborations; (vii) loss of key
management personnel; (viii) the scope of protection the Company is
able to establish and maintain for intellectual property rights
covering its products and its ability to operate its business
without infringing the intellectual property rights of others; (ix)
potential failure to comply with applicable health information
privacy and security laws and other state and federal privacy and
security laws; and (x) the difficulty of predicting actions of the
USA FDA and its regulations. All forward-looking statements
included in this press release are made only as of the date of this
press release. The Company assumes no obligation to update any
written or oral forward-looking statement unless required by law.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
contained under the heading "Risk Factors" in Ehave, Inc.’s
Registration Statement on Form F-1 filed with the Securities and
Exchange Commission (SEC) on September 24, 2015, as amended, which
is available on the SEC's website, http://www.sec.gov.
For Investors Relations, please contact:
Gabe Rodriguez
Phone: (623) 261-9046
Email: ir@ehave.com
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Apr 2023 to Apr 2024